文献速递外周动脉疾病

糖尿病股腘动脉病变中Chocolate Touch与Lutonix药物涂层球囊的对比:Chocolate Touch研究

Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study.
PubMed 文献 · J Endovasc Ther · 2023-06-14

Chocolate Touch随机试验的预设糖尿病亚组分析,比较糖尿病与非糖尿病患者中Chocolate Touch与Lutonix药物涂层球囊治疗股腘动脉病变的结局。糖尿病组12个月DCB成功率为77.2% vs 60.5%(p=0.08),非糖尿病组为80% vs 71.3%(p=0.2114),主要安全终点在有无糖尿病各组间相似(交互检验p=0.96)。结论为无论糖尿病状态如何,两种球囊在12个月时的安全性和有效性相似。

要点

  • 糖尿病组12个月DCB成功率Chocolate Touch 77.2% vs Lutonix 60.5%(p=0.08)。
  • 非糖尿病组12个月DCB成功率Chocolate Touch 80% vs Lutonix 71.3%(p=0.2114)。
  • 主要安全终点在有无糖尿病各队列间相似(交互检验p=0.96)。

核心结论

  • 该随机试验表明,无论糖尿病状态如何,Chocolate Touch药物涂层球囊与Lutonix药物涂层球囊治疗股腘动脉病变在12个月时的安全性和有效性相似。

研究设计与样本

  • Chocolate Touch研究的预设糖尿病亚组分析,纳入有跛行或缺血性静息痛(Rutherford 2-4级)的患者,随机分配至Chocolate Touch或Lutonix药物涂层球囊。
  • 共313例患者(38%为糖尿病,n=119)被随机分配至Chocolate Touch(n=66/152)或Lutonix药物涂层球囊(n=53/161)。

主要发现

  • 糖尿病组中,Chocolate Touch与Lutonix药物涂层球囊的DCB成功率分别为77.2%和60.5%(p=0.08)。
  • 非糖尿病组中,Chocolate Touch与Lutonix药物涂层球囊的DCB成功率分别为80%和71.3%(p=0.2114)。
  • 主要安全终点在有无糖尿病各队列间相似(交互检验p=0.96)。

关键数值与推荐

  • 主要疗效终点DCB成功定义为12个月时原发性通畅(双功超声峰值收缩速度比<2.4,无临床驱动的靶病变血运重建,且无补救性支架置入)。
  • 主要安全终点为12个月时无主要不良事件,即靶肢体相关死亡、重大截肢或再干预的复合终点。

临床怎么用

  • 作者指出,无论糖尿病状态如何,血管内治疗已成为大多数有症状股腘动脉病变的首选治疗。
  • 作者认为这些结果为临床医生在该高危患者群体中治疗股腘动脉病变提供了另一种选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The randomized Chocolate Touch Study demonstrated that in patients undergoing treatment of femoropopliteal artery lesions, the Chocolate Touch drug-coated balloon (DCB) was safe and had superior efficacy at 12 months compared with the Lutonix DCB. We report the prespecified diabetes subanalysis comparing outcomes among patients with and without diabetes mellitus (DM). METHODS: Patients with claudication or ischemic rest pain (Rutherford class 2-4) were randomized to Chocolate Touch or Lutonix DCB. The primary efficacy endpoint was DCB success defined as primary patency at 12 months (peak systolic velocity ratio <2.4 by duplex ultrasound without clinically driven target lesion revascularization in the absence of bailout stenting). The primary safety endpoint was freedom from major adverse events at 12 months, a composite of target limb-related death, major amputation, or reintervention. RESULTS: A total of 313 patients (38% DM [n=119]) were randomized to either Chocolate Touch (n=66/152) or Lutonix DCB (n=53/161). Among patients with DM, DCB success was 77.2% and 60.5% (p=0.08), and in non-DM patients, DCB success was 80% and 71.3% (p=0.2114) for the Chocolate Touch and Lutonix DCB, respectively. The primary safety endpoint was similar for both cohorts regardless of DM status (interaction test, p=0.96). CONCLUSIONS: This randomized trial demonstrated similar safety and efficacy for the treatment of femoropopliteal disease with the Chocolate Touch DCB compared with using the Lutonix DCB regardless of DM status at 12 months.Clinical ImpactThis substudy of the Chocolate Touch Study demonstrated similar safety and efficacy for treatment of femoropopliteal disease of the Chocolate Touch DCB compared with the Lutonix DCB regardless of diabetes (DM) status at 12 months. Endovascular therapy has become the therapy of choice for the treatment of most symptomatic femoropopliteal lesions regardless of DM status. These results give clinicians another option when treating femoropopliteal disease in this high-risk patient population.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Böhme T, Zeller T, Shishehbor MH, et al. Chocolate Touch Versus Lutonix Drug-Coated Balloon for Femoropopliteal Lesions in Diabetes: The Chocolate Touch Study. J Endovasc Ther. 2023. PMID: 37314243. doi:10.1177/15266028231179589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。